 SEATTLE, WA and VANCOUVER, BC ACCESSWIRE March 11, 2021 Achieve Life Sciences, Inc. NASDAQ:ACHV, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program. Recent Events Highlights Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States Presented data on smoker and e-cigarette user attitudes and perceptions on quitting at the Society for Research on Nicotine and Tobacco SRNT Annual Meeting on February 24, 2021 Closed financing of 17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses, in December 2020 Facilitated Smoking Cessation Key Opinion Leader Virtual Roundtable in November 2020 We concluded 2020 in the best financial position since the Companys inception and with the Phase 3 ORCA-2 trial underway at 15 well-established smoking cessation research centers in the United States. 